SecBot SecBot
8-K ·Filed Jun 1, 2026

ESPR

Esperion Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonimmediate Processed5mo ago SEC0001628280-26-039518
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Routine annual meeting results filing with no immediate trading catalyst. Monitor future equity grant activity under the expanded plan for potential dilution, but no action warranted based on this filing alone.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$3.14
T+0 close · Jun 1, 2026 · via day close
Latest settled
+0.64%
T+20 · $3.16
Vs SPY
+2.20%
α at T+20
Next horizon
T+60
due 3mo ago
  1. T+0 · Jun 2 $3.14entry
  2. T+1 · 6mo ago 0.00%α +0.72% · $3.14
  3. T+5 · 5mo ago 0.00%α +2.96% · $3.14
  4. T+20 · 5mo ago +0.64%α +2.20% · $3.16
  5. T+60 · due 3mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Esperion Therapeutics filed an 8-K reporting the results of its 2026 annual meeting of stockholders held on May 28, 2026. Stockholders approved all four proposals, including the re-election of two Class I directors (J. Martin Carroll and Sheldon L. Koenig), a non-binding advisory vote on executive compensation, ratification of Ernst & Young as independent auditor, and a Fourth Amendment to the 2022 Stock Option and Incentive Plan increasing authorized shares by 7,000,000 to a total of 30,150,000 shares. This is a routine post-meeting filing with no material financial impact.

Key Facts

  • Annual meeting held May 28, 2026; all four stockholder proposals approved.
  • Class I directors J. Martin Carroll and Sheldon L. Koenig re-elected.
  • Fourth Amendment to 2022 Stock Option and Incentive Plan approved, increasing authorized shares by 7,000,000 to 30,150,000 total.
  • 257,404,876 shares of common stock outstanding as of March 31, 2026 record date.
  • Ernst & Young LLP ratified as independent auditor for fiscal year ending December 31, 2026.

Financial Impact

No financial figures reported. The 7,000,000 share increase to the equity incentive plan is a routine authorization; no actual issuance or dilution occurred with this filing.

dilution

Risk Factors

  • Potential future dilution from equity awards under the expanded 2022 Plan, though no grants are disclosed in this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-039518
Document: espr-20260528.htm0001628280-26-039518
Document: 0001628280-26-039518-index-headers.html0001628280-26-039518
Document: 0001628280-26-039518-index.html0001628280-26-039518
Document: 0001628280-26-039518.txt0001628280-26-039518

Track record

21 reports on ESPR

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.30% at T+60 after the Mar 10, 2026 report. 6 of 8 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
  2. Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
  3. Aug 13, 202613w ago Institutional Cluster Bearish 5/10 No price data
  4. Jul 23, 202616w ago 15-12G Neutral 5/10 No price data
  5. Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
  6. Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
  7. Jul 13, 202618w ago 25-NSE Bullish 7/10 Entry $3.19 No price data
  8. Jul 13, 202618w ago 8-K Bullish 7/10 Entry $3.19 No price data
  9. Jun 16, 202621w ago DEFA14A Bullish 6/10 Entry $3.17 No price data
  10. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 5, 2026